Clinical trial register · Germany

Clinical Trials in Regensburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 20 Oct 2026, 03:18 UTC

5062

Studies in scope

all four open statuses

2873

Recruiting now

open to new participants

988

Lead sponsors

across recruiting studies

Top sites

Berlin 1586 Hamburg 889 Essen 766 Dresden 716 Heidelberg 627

Trials with a site in Regensburg

Status

Study

Lead sponsor

Phase

Enrol

Sites in Germany

Start

Not yet open

Dalbavancin Therapy for Infective Endocarditis

NCT07699211Endocarditis Infective, Endocarditis, Bacterial

DrugDalbavancin administration

Stefan Hagel

Phase 3

184

Freiburg im Breisgau, Regensburg, Hamburg, Cologne, Leipzig, Berlin, Erfurt, Jena

2026-12

Not yet open

A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

NCT07830732Haemophilia A

Novo Nordisk A/S

Phase 3

Berlin, Bonn, Hanover, Leipzig, Regensburg

2026-10-09

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

NCT07680790Non-Small Cell Lung Cancer

DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin

Bristol-Myers Squibb

Phase 3

850

Gerlingen, Munich, Regensburg, Frankfurt am Main, Oldenburg, Cologne, Dortmund, Essen

2026-09-08

Not yet open

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

NCT07178730Breast Cancer, Triple-negative Breast Cancer

DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab

Women's Cancer Study Group GmbH

Phase 3

765

Heilbronn, Weinheim, Augsburg, München, Regensburg, Würzburg, Cottbus, Bad Nauheim

2026-08-30

Recruiting

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)

NCT07739914Liver Allograft, Liver Diseases, Liver Transplantation

DrugsCyclosporine·Tacrolimus·Everolimus

Hannover Medical School

Phase 3

150

Heidelberg, Tübingen, Regensburg, Würzburg, Hamburg, Hanover, Rostock, Aachen

2026-08-19

Recruiting

Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention

NCT07649681Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer)

Wuerzburg University Hospital

Not applicable

198

Augsburg, Erlangen, München, Regensburg, Würzburg

2026-07-24

Recruiting

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

NCT07387198Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

135

Heidelberg, Mannheim, Tübingen, Regensburg, Würzburg, Hamburg, Frankfurt am Main, Bielefeld

2026-05-29

Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 2

Berlin, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Regensburg

2026-05-20

Recruiting

Multicenter Study for Diagnostic Validation of a Laboratory Test for the Diagnosis of Endometriosis

NCT07553676Endometriosis

Diamens FlexCo

Observational

200

Karlsruhe, Regensburg

2026-05-06

Recruiting

Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons

NCT07788729Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer

University of Regensburg

Not applicable

384

Augsburg, Erlangen, Regensburg, Würzburg, Bayreuth, Berlin, Cologne

2026-04-21

Recruiting

Accelerated Treatment of Depressive Patients With tDCS

NCT07444242Major Depressive Disorder

University of Regensburg

Not applicable

Regensburg

2026-04-01

Recruiting

Vorasidenib Maintenance for IDH Mutant Astrocytoma

NCT06809322IDH-mutant Grade 2 or 3 Astrocytoma

DrugVorasidenib

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

468

Bonn, Frankfurt, Heidelberg, Mannheim, Regensburg

2026-01-16

Recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion

DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2/3

590

Göppingen, Stuttgart, Tübingen, Ulm, Donauwörth, München, Regensburg, Traunstein

2026-01-02

Recruiting

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569Hidradenitis Suppurativa

Sanofi

Phase 2

144

Blankenfelde-Mahlow, Darmstadt, Dresden, Merzig, Regensburg, Rostock

2025-12-29

Recruiting

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

NCT07218523Bowel Cleansing Prior to Clinical Procedures

DrugsPicoprep·Plenvu

Norgine

Phase 3

212

Regensburg, Münster, Wuppertal, Mainz, Berlin

2025-12-29

Recruiting

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

NCT06975787Lupus Nephritis (LN)

DrugsVonsetamig·Odronextamab

Regeneron Pharmaceuticals

Phase 1

Regensburg, Mainz

2025-12-22

Recruiting

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

NCT07110038Penile Squamous Cell Carcinoma (PSCC)

DrugsAvelumab·Enfortumab Vedotin

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

Dresden, Düsseldorf, Mainz, Mannheim, Munich, München, Regensburg, Rostock

2025-12-16

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

500

Bonn, Essen, Frankfurt, Giessen, Hanover, Leipzig, Regensburg, Rostock

2025-12-03

Recruiting

Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders

NCT07040189Multiple Myeloma, GI Cancer, Taste Disorders

Wuerzburg University Hospital

Not applicable

Munich, Regensburg, Würzburg

2025-11-25

Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 1/2

152

München, Münster, Oldenburg, Regensburg, Würzburg

2025-11-24

Recruiting

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101Ulcerative Colitis

DrugsZotemtegrast·Mirikizumab

Eli Lilly and Company

Phase 2

252

Berlin, Dachau, Erlangen, Regensburg, Ulm

2025-11-10

Active, closed

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820Pulmonary Hypertension

Pfizer

Phase 2

Heidelberg, Regensburg, Giessen, Greifswald, Dresden

2025-11-10

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Heidelberg, Nürtingen, Munich, Nuremberg, Regensburg, Hanover, Kiel, Jena

2025-09-30

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

Cologne, Herne, Leverkusen, Mannheim, Nürtingen, Regensburg

2025-09-10

Recruiting

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

NCT05690048Immunotherapy, HCC - Hepatocellular Carcinoma

DrugsVancomycin·Atezolizumab·Bevacizumab

Michael Dill

Phase 2

Heidelberg, Augsburg, Essen, Mannheim, Regensburg, Tübingen, Ulm

2025-07-16

Recruiting

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

NCT06988605Atopic Dermatitis

Galderma R&D

Observational

1,000

Karlsruhe, Langenau, Augsburg, Erlangen, Regensburg, Remscheid, Ahaus, Berlin

2025-07-14

Recruiting

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta

W.L.Gore & Associates

Observational

1,500

Bonn, Frankfurt, Regensburg, Ulm

2025-06-19

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Freiburg im Breisgau, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main, Essen, Minden

2025-06-17

Recruiting

Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time

NCT06874296Liver Transplantation, Liver Diseases, Surgery

Charite University, Berlin, Germany

Not applicable

186

Hamburg, Aachen, Bonn, Münster, Berlin, Hanover, München, Regensburg

2025-06-02

Recruiting

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

NCT06897839Bronchopulmonary Dysplasia

Airway Therapeutics, Inc.

Phase 2/3

366

Dresden, Freiburg im Breisgau, Regensburg

2025-02-03

Active, closed

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

NCT06478212IDH1-mutant Glioma, IDH2-mutant Glioma

DrugsVorasidenib·Temozolomide

Institut de Recherches Internationales Servier

Phase 1/2

Heidelberg, Mannheim, Regensburg

2025-01-22

Recruiting

The PERSEVERE Study

NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism

Inari Medical

Not applicable

200

Kiel, Berlin, Chemnitz, Dresden, Mainz, München, Regensburg

2024-12-16

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858Candidemia, Candidiasis, Invasive

DrugsCaspofungin·Fosmanogepix·Fluconazole

Basilea Pharmaceutica

Phase 3

450

Ulm, Regensburg, Frankfurt am Main, Giessen, Cologne, Heidelberg

2024-12-11

Active, closed

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT06685757Antibody-mediated Rejection

DrugFelzartamab

Biogen

Phase 3

132

Berlin, Dresden, Hamburg, Regensburg

2024-12-03

Recruiting

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension

Novartis Pharmaceuticals

Phase 1/2

232

Regensburg, Dresden, Berlin, Giessen, Greifswald, Heidelberg, Homburg

2024-10-24

Active, closed

A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

NCT06551519Multiple Sclerosis

Novartis Pharmaceuticals

Observational

519

Albstadt, Mannheim, Schwetzingen, Bamberg, Neuburg A.d. Donau, Regensburg, Unterhaching, Untermeitingen

2024-10-23

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Frankfurt am Main, Freiburg I. Breisgau, Hamburg, Jena, Mannheim, Regensburg

2024-10-11

Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 1

220

Regensburg, Würzburg

2024-10-07

Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

Stemline Therapeutics, Inc.

Phase 3

4,220

Mannheim, Ulm, Augsburg, Eggenfelden, Erlangen, München, Regensburg, Rüdersdorf

2024-09-27

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

Freiburg im Breisgau, Ulm, Munich, Regensburg, Würzburg, Giessen, Buxtehude, Bochum

2024-09-18

Recruiting

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

NCT06517719Metastatic Castration Resistant Prostate Cancer

Novartis Pharmaceuticals

Observational

500

Konstanz, Stuttgart, Munich, Regensburg, Würzburg, Cottbus, Frankfurt (Oder), Ludwigshafen

2024-09-04

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsTrosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Munich, Regensburg, Frankfurt am Main, Fulda

2024-09-04

Active, closed

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

NCT06425302Lymphoma, Follicular

DrugsEndoxan·Golcadomide·Pegylated liposomal doxorubicin·Bendamustine

Celgene

Phase 2

Regensburg, Chemnitz, Dresden

2024-08-30

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Munich, Regensburg, Würzburg, Frankfurt am Main, Bochum, Essen

2024-07-31

Active, closed

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor

DrugsTemodar·Niraparib·Temozolomide

Ivy Brain Tumor Center

Phase 3

450

Heidelberg, Mannheim, Tübingen, Regensburg, Bonn, Chemnitz, Leipzig, Berlin

2024-06-19

Not yet open

Autologous Muscle Stem Cell Therapy for Treatment of Congenital Urinary Incontinence in Epispadias Patients

NCT04729582Urinary Incontinence, Epispadias, Male

Simone Spuler, MD

Phase 1/2

Regensburg, Ulm

2024-06

Active, closed

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731Age Related Macular Degeneration (ARMD)

DrugElamipretide

Stealth BioTherapeutics Inc.

Phase 3

313

Münster, Regensburg, Tübingen

2024-05-30

Recruiting

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

NCT06137378Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV

DrugsKeytruda·Pembrolizumab

University of Leipzig

Phase 2

140

Mannheim, Ulm, München, Regensburg, Würzburg, Potsdam, Cologne, Leipzig

2024-04-17

Active, closed

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

NCT05871021Glioblastoma

University Hospital Tuebingen

Phase 2

107

Augsburg, Cologne, Frankfurt, Freiburg im Breisgau, Leipzig, Mannheim, Munich, Regensburg

2024-04-10

Recruiting

Cohort Study on Plant-based Diets (COPLANT Study)

NCT06323538Dietary Exposure, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Bone Loss

German Federal Institute for Risk Assessment

Observational

6,000

Karlsruhe, Jena, Berlin, Bonn, Giessen, Heidelberg, Regensburg

2024-04-09

Recruiting

Prospective, Non-Randomised Clinical Trial to Investigate the BeGraft Aortic Stent Graft System and the BeGraft Peripheral Stent Graft System Treating Aortic-iliac Occlusive Disease

NCT05805111Aorto-iliac Occlusive Disease

Marc Bosiers, MD

Observational

109

Berlin, Frankfurt, Göttingen, Heidelberg, Lünen, Münster, Regensburg, Stuttgart

2024-04-05

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Esslingen am Neckar, Regensburg, Hemer, Koblenz, Leipzig, Halle, Bad Berka, Gera

2024-04-03

Active, closed

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767Bladder Cancer

DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

230

Munich, Regensburg, Dresden, Halle, Berlin

2024-03-28

Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

NCT05904119First Progression of Glioblastoma

DrugLomustine

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

411

Bochum, Cologne, Erlangen, Essen, Heidelberg, Leipzig, Munich, Regensburg

2024-03-15

Recruiting

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081Early Breast Cancer

DrugsLeuprolide·Goserelin·Exemestane·Ribociclib

Novartis Pharmaceuticals

Phase 3

1,444

Freiburg im Breisgau, Munich, Regensburg, Weiden in Der Oberpfalz, Langen, Hildesheim, Bergisch Gladbach, Bielefeld

2024-02-28

Recruiting

Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL

NCT06134492Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex

DrugAcyclovir

Jena University Hospital

Phase 3

616

Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Nuremberg, Regensburg, Rosenheim

2024-02-20

Recruiting

Improvement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer

NCT06252233Lung Cancer, Quality of Life

University of Bayreuth

Not applicable

220

Bamberg, Bayreuth, Coburg, Donaustauf, Kulmbach, Regensburg, Straubing

2024-02-15

Active, closed

Registry Study on Prescription, Patient Pathways, Therapy Efficacy and Usage of Mandibular Advancement Devices in Obstructive Sleep Apnea - PATT-OSA Registry

NCT03924817Obstructive Sleep Apnea

ResMed

Observational

500

Blaubeuren Abbey, Essen, Berlin, Regensburg

2024-02-01

Recruiting

OSsIRIS Study - A Post-market Clinical Follow-up Investigation.

NCT06156904Surgically Created Bone Defects or Bone Defects/Voids Resulting From Traumatic Injury

GreenBone Ortho S.p.A.

Observational

135

Berlin, Regensburg

2024-01-31

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Kiel, Münster, Regensburg

2024-01-23

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197Heart Failure, Acute Heart Failure

DrugsKerendia·Finerenone

Colorado Prevention Center

Phase 3

5,200

Lübeck, Berlin, Jena, Dresden, Giessen, Regensburg

2024-01-17

Active, closed

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

NCT05568459Hemophilia B

Regeneron Pharmaceuticals

Observational

Regensburg, Frankfurt, Hamburg

2024-01-17

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157Neoplasms

DrugsMomelotinib·Ruxolitinib

Janssen Research & Development, LLC

Phase 1

300

Aachen, Berlin, Essen, Hanover, Heidelberg, Regensburg

2023-12-20

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Freiburg im Breisgau, Heidelberg, Nürtingen, Munich, Regensburg, Marburg, Göttingen, Bergisch Gladbach

2023-12-18

Active, closed

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

285

Hamburg, Giessen, München, Regensburg

2023-12-18

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

Esslingen am Neckar, Gauting, Kempten (Allgäu), Regensburg, Bochum, Münster, Paderborn, Großhansdorf

2023-12-06

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Frankfurt am Main, Essen, Aachen, Berlin, Giessen, Hamburg, Regensburg, Ulm

2023-11-14

Recruiting

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

NCT05811364Aortoiliac Occlusive Disease, Peripheral Arterial Disease

W.L.Gore & Associates

Not applicable

244

Bad Krozingen, Münster, Regensburg, Stuttgart

2023-10-17

Recruiting

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

NCT06223711Extensive-stage Small-cell Lung Cancer

DrugDurvalumab

Universität des Saarlandes

Phase 2

Augsburg, Erlangen, Regensburg, Mönchengladbach, Homburg

2023-10-06

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

NCT06006117Marginal Zone Lymphoma

DrugsMosunetuzumab·Bendamustine·Lenalidomide·Rituximab

The Lymphoma Academic Research Organisation

Phase 3

260

Amberg, Berlin, Kiel, Ludwigshafen, Regensburg, Stuttgart, Trier, Ulm

2023-09-05

Recruiting

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

NCT05958121Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer

Immatics Biotechnologies GmbH

Phase 1/2

400

Heidelberg, Mannheim, Tübingen, Ulm, Erlangen, Nuremberg, Regensburg, Würzburg

2023-08-09

Recruiting

TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study

NCT05538806Pleural Mesothelioma

NovoCure Ltd.

Observational

198

Gauting, Regensburg, Harburg, Bremen, Göttingen, Dresden, Berlin, Cologne

2023-08-01

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

DrugZipalertinib

Taiho Oncology, Inc.

Phase 2

220

Kassel, Dresden, Giessen, Regensburg

2023-07-31

Recruiting

Lung cAncer Robotic Comparative Study

NCT06038227Lung Cancer

Intuitive Surgical

Observational

600

Heidelberg, Regensburg

2023-07-15

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Freiburg im Breisgau, Erlangen, Regensburg, Würzburg, Frankfurt am Main, Bad Bentheim, Bramsche, Düsseldorf

2023-06-21

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Mannheim, Regensburg

2023-06-05

Active, closed

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

NCT05433116Head and Neck Squamous Cell Carcinoma

DrugsLenvatinib·Keytruda·Pembrolizumab

Universität des Saarlandes

Phase 2

Ulm, Augsburg, Erlangen, Regensburg, Frankfurt am Main, Giessen, Düsseldorf, Homburg

2023-05-25

Recruiting

Intermittent Theta Burst Stimulation for Maintenance Therapy in Depression

NCT05732311Depression

Berthold Langguth, MD, Ph.D.

Not applicable

Regensburg

2023-04-25

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

NCT05816382Narcolepsy Type 1

DrugTAK-861

Takeda

Phase 2/3

500

Regensburg, Schwerin, Berlin, Hamburg

2023-04-05

Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Observational

1,650

Bochum, Bonn, Cologne, Essen, Frankfurt, Jena, Leipzig, Regensburg

2023-03-21

Active, closed

Application of Direct Current Transcranial stImulation, Remotely superVised in Chronic fATiguE

NCT05791812Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

University of Regensburg

Not applicable

Regensburg

2023-03-16

Active, closed

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399Melanoma

DrugsPhesgo·Relatlimab·Nivolumab

Bristol-Myers Squibb

Phase 3

579

Heidelberg, Ulm, Regensburg, Lübeck, Berlin, Buxtehude, Dortmund, Erfurt

2023-03-06

Recruiting

High-dose Accelerated Theta Burst Stimulation for the Treatment of Alcohol Addiction

NCT05738174Alcohol Dependence

Berthold Langguth, MD, Ph.D.

Not applicable

Regensburg

2023-03-01

Active, closed

Theta Burst Stimulation in Pharmacologically Untreated Patients as Sole Antidepressant Treatment

NCT05732298Depression

University of Regensburg

Not applicable

Regensburg

2023-02-27

Active, closed

Registry on Percutaneous Electrochemotherapy

NCT05267080Primary Liver Cancer, Secondary Liver Cancer

Cardiovascular and Interventional Radiological Society of Europe

Observational

250

Bonn, Braunschweig, Halle, Leipzig, Regensburg

2023-01-25

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Heidelberg, Augsburg, Regensburg, Frankfurt am Main, Bonn, Cologne, Essen, Berlin

2023-01-23

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

Mannheim, Tübingen, Augsburg, Erlangen, Munich, Regensburg, Darmstadt, Frankfurt am Main

2023-01-16

Active, closed

TARGET Study: Safety and Performance of the Cardiovalve TR Replacement System

NCT05486832Tricuspid Regurgitation

Cardiovalve Ltd.

Not applicable

157

Bad Oeynhausen, Berlin, Bonn, Cologne, Hamburg, Lübeck, Regensburg

2022-12-09

Active, closed

Mesh Augmented Reinforcement of Abdominal Wall Suture Line to Limit the Rate of Incisional Hernia Occurrence

NCT05424484Incisional Hernia, Incisional Hernia of Midline of Abdomen, Midline Laparotomy

Medtronic - MITG

Not applicable

123

Braunschweig, Oldenburg, Regensburg

2022-11-22

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839Relapsed/Refractory Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Lenalidomide

AbbVie

Phase 1

283

Tübingen, Regensburg, Würzburg, Essen, Hamburg

2022-10-20

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Heidelberg, Tübingen, Erlangen, Munich, Regensburg, Würzburg, Bad Bentheim, Buxtehude

2022-09-13

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Berlin, Essen, Hanover, München, Regensburg

2022-09-06

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Berlin, Buxtehude, Heidelberg, Heilbronn, Kiel, Mainz, München, Regensburg

2022-08-11

Recruiting

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

NCT05442710Sepsis, Severe

Artcline GmbH

Phase 2

142

Freiburg im Breisgau, Regensburg, Bonn, Cologne, Aue, Leipzig, Halle, Kiel

2022-07-24

Active, closed

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

NCT05352672Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,546

Mannheim, Tübingen, Munich, Nuremberg, Regensburg, Frankfurt am Main, Giessen, Buxtehude

2022-07-14

Recruiting

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

NCT05045664Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a

Heidelberg University

Phase 3

100

Berlin, Essen, Göttingen, Heidelberg, Mönchengladbach, Munich, Regensburg, Rostock

2022-07-06

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Ulm, Augsburg, Regensburg, Würzburg, Marburg, Leipzig

2022-06-14

Active, closed

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

NCT05359445Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer

DrugsKeytruda·Pembrolizumab

Immatics Biotechnologies GmbH

Phase 1

Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Erlangen, Munich, Nuremberg, Regensburg

2022-05-19

Recruiting

Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®

NCT05114850Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure

P+F Products + Features GmbH

Observational

450

Freiburg im Breisgau, Friedrichshafen, Heilbronn, Regensburg, Stuttgart, Winnenden

2022-04-20

Recruiting

Zimmer® Natural Nail® (ZNN) Bactiguard Tibia Post-Market Clinical Follow-up Study

NCT05022485Tibial Fractures, Fracture Infection

Zimmer Biomet

Observational

500

Marburg, Leipzig, Regensburg

2022-04-11

Active, closed

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

MaaT Pharma

Phase 3

Berlin, Mannheim, Regensburg, Ulm, Würzburg

2022-03-25

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

NCT05031780Sickle Cell Disease

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 2/3

286

Essen, Regensburg

2022-02-11

Active, closed

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097Relapsed or Refractory Follicular Lymphoma

DrugsMosunetuzumab·Lenalidomide·Rituximab

Hoffmann-La Roche

Phase 3

478

Berlin, Dresden, Halle, Heidelberg, Regensburg, Rostock, Ulm

2021-10-27

Active, closed

Study of Lacutamab in Peripheral T-cell Lymphoma

NCT04984837Peripheral T Cell Lymphoma, Relapse/Recurrence

DrugsOxaliplatine·Gemcitabine

The Lymphoma Academic Research Organisation

Phase 2

Berlin, Goettigen, Halle, Leipzig, Regensburg

2021-10-05

Active, closed

Plasma On Chronic Wounds for Epidermal Regeneration

NCT05855499Chronic Ulcer of Lower Extremity

Coldplasmatech

Not applicable

120

Tübingen, München, Regensburg, Hamburg, Bochum, Dresden, Berlin, Saalfeld

2021-10-01

Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

European Foundation for Study of Chronic Liver Failure

Observational

3,000

Regensburg, Kiel, Aachen, Berlin, Frankfurt, Hamburg, Hanover, Heidelberg

2021-07-08

Recruiting

A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

NCT04201210HbS Disease, Hemoglobin S Disease, Sickle Cell Anemia, Sickle Cell Disorders

University of Regensburg

Phase 2

212

Aachen, Berlin, Düsseldorf, Frankfurt, Heidelberg, Regensburg, Tübingen, Würzburg

2021-06-30

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Heidelberg, Munich, Regensburg, Giessen, Hanover, Cologne, Dresden, Leipzig

2021-05-12

Recruiting

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis

AgNovos Healthcare, LLC

Not applicable

2,400

Berlin, Düsseldorf, Giessen, Hanover, Kiel, München, Münster, Regensburg

2021-04-24

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

808

Freiburg im Breisgau, Tübingen, Regensburg, Würzburg, Herne, Münster, Dresden, Halle

2021-04-21

Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576Chronic Graft-versus-host-disease

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

296

Dresden, Jena, Leipzig, Mainz, Münster, Regensburg

2021-03-04

Active, closed

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638Diffuse Large B-cell Lymphoma

DrugsRituxumab·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

270

Frankfurt, Giessen, Regensburg

2021-02-23

Active, closed

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659Sickle Cell Disease

DrugEtavopivat

Forma Therapeutics, Inc.

Phase 3

450

Berlin, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Regensburg

2021-01-29

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Berlin, Dessau-RoBlau, Essen, Freiburg im Breisgau, Mönchengladbach, München, Münster, Regensburg

2021-01-28

By invitation

A Long-term Follow-up Study in Participants Who Received CTX001

NCT04208529Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases

DrugExa-cel

Vertex Pharmaceuticals Incorporated

Phase 3

160

Düsseldorf, Klinik Für Kinder- Und Jugendmedizin, Regensburg

2021-01-20

Active, closed

ACURATE neo2™ Post Market Clinical Follow up Study

NCT04655248Aortic Valve Stenosis, Aortic Valve Calcification, Aortic Diseases

Boston Scientific Corporation

Observational

250

Bad Nauheim, Bad Oeynhausen, Dortmund, Regensburg

2020-12-16

Recruiting

LANDMARK Trial: a Randomised Controlled Trial of Myval THV

NCT04275726Aortic Valve Stenosis

Meril Life Sciences Pvt. Ltd.

Not applicable

988

Bad Nauheim, Leipzig, Bad Krozingen, Braunschweig, Dresden, Hamburg, Regensburg

2020-11-04

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Regensburg, Frankfurt am Main, Hanover, Lüneburg

2020-09-30

Active, closed

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

NCT04503278Solid Tumor

BioNTech Cell & Gene Therapies GmbH

Phase 1

214

Berlin, Cologne, Erlangen, Hamburg, Hanover, Heidelberg, Mainz, Regensburg

2020-09-16

Active, closed

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

NCT04245839Lymphoma, Non-Hodgkin

DrugsLiso-cel·Fludarabine·Cyclophosphamide

Celgene

Phase 2

276

Ulm, Regensburg, Cologne, Karlsruhe, Munich

2020-07-14

Active, closed

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945Pulmonary Arterial Hypertension

DrugMacitentan

Actelion

Phase 3

935

Bad Oeynhausen, Hanover, München, Regensburg

2020-06-30

Active, closed

Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease

NCT04291261Acute-graft-versus-host Disease

DrugUvadex

Universitätsklinikum Hamburg-Eppendorf

Phase 2

Hamburg, Erlangen, Regensburg

2020-05-18

Active, closed

rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia

NCT04318977Negative Symptoms With Primary Psychotic Disorder, Schizophrenia

University of Regensburg

Not applicable

Aachen, Regensburg

2020-02-01

Active, closed

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsMobocertinib·Pemetrexed·Cisplatin·Carboplatin

Takeda

Phase 3

354

Heidelberg, München, Regensburg, Frankfurt am Main, Oldenburg, Berlin

2020-01-10

Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447Glioblastoma

DrugsAZD1390·Troriluzole·Paxalisib·Pegargiminase

Global Coalition for Adaptive Research

Phase 2/3

2,250

Cologne, Frankfurt, Heidelberg, Mannheim, Regensburg, Tübingen

2019-07-30

Recruiting

COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer

NCT05906407Early-Stage Breast Cancer, Neoadjuvant Therapy

German Cancer Research Center

Observational

2,000

Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg

2019-04-19

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Dresden, Göttingen, Halle, Hanover, Heidelberg, Homburg, Regensburg, Trier

2019-03-06

Active, closed

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

NCT03768063Cancer

DrugsEmactuzumab·Rucaparib·Cobimetinib·Vemurafenib

Hoffmann-La Roche

Phase 3

1,000

Ulm, Regensburg, Lübeck, Essen, Freiburg im Breisgau, Gauting, Gera, Immenhausen

2019-02-28

Active, closed

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962Focal Epilepsy

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 2

325

Berlin, Bielefeld, Bonn, Frankfurt, Freiburg im Breisgau, Münster, Osnabrück, Regensburg

2019-01-30

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main

2018-04-09

Active, closed

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373Neuroblastoma

DrugsNaxitamab·Gm-Csf

Y-mAbs Therapeutics

Phase 2

122

Hamburg, Mainz, Regensburg

2018-04-03

Recruiting

Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis

NCT03334006Peritonitis, Sepsis, Septic Shock

RWTH Aachen University

Phase 2

200

Tübingen, Regensburg, Essen, Berlin, Aachen, Bochum, Dortmund, Dresden

2017-11-20

Recruiting

Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma

NCT03222635Submucosal Esophageal Adenocarcinoma, Barrett Esophagus, High-risk Mucosal Esophageal Adenocarcinoma

Amsterdam UMC

Not applicable

225

Augsburg, Düsseldorf, Münich, Regensburg

2017-07-25

Recruiting

CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

NCT05652569Metastatic Breast Cancer

German Cancer Research Center

Observational

5,000

Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg

2017-06-12

Active, closed

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608Carcinoma, Non-Small-Cell Lung

DrugsCrizotinib·Lorlatinib

Pfizer

Phase 3

296

Dresden, Heidelberg, Homburg - Saar, Regensburg

2017-04-27

Active, closed

Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients

NCT04186208Cartilage Disease

DrugNOVOCART 3D

Tetec AG

Observational

Mannheim, Stuttgart, München, Regensburg, Kiel

2017-04-25

Active, closed

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872Small Cell Lung Carcinoma Extensive Disease

DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin

AstraZeneca

Phase 3

987

Aachen, Berlin, Gauting, Gera, Hamburg, Heidelberg, Mainz, Regensburg

2017-03-27

Recruiting

Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses

NCT04108936Peritoneal Carcinomatosis

University of Regensburg

Observational

250

Regensburg

2016-10

Active, closed

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

NCT02584933ALK Positive Malignancies

DrugCeritinib

Novartis Pharmaceuticals

Phase 4

233

Regensburg, Cologne, Essen, Heidelberg, Würzburg

2015-12-11

Recruiting

CAR-T Long Term Follow Up (LTFU) Study

NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

Novartis Pharmaceuticals

Phase 3

1,105

Munich, Regensburg, Würzburg, Frankfurt am Main, Cologne, Leipzig, Berlin, Hamburg

2015-11-02

Active, closed

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

NCT00626990Brain and Central Nervous System Tumors

DrugsTemodal·Temodar·Temozolomide

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

751

Bamberg, Bonn, Hanover, Heidelberg, Regensburg, Tübingen

2007-12

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-germany/city/regensburg

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 20 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 141 of those studies with a site in Regensburg.

How many clinical trials are recruiting in Regensburg?

74 of the 141 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:18 UTC sync. A further 4 have not yet opened recruitment, 62 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Regensburg), 141 studies
Phase	Studies	Recruiting	Share
Phase 3	50	18	35.5%
Phase 2	29	15	20.6%
Observational	22	16	15.6%
Not applicable	19	13	13.5%
Phase 1/2	7	4	5%
Phase 2/3	7	5	5%
Phase 1	6	3	4.3%
Phase 4	1	0	0.7%

Most active sponsors

Lead sponsors with the most studies (Regensburg)
Lead sponsor	Studies	Recruiting
AstraZeneca	7	3
Novartis Pharmaceuticals	7	4
University of Regensburg	7	4
AbbVie	6	1
Merck Sharp & Dohme LLC	6	2
Regeneron Pharmaceuticals	5	1
Bristol-Myers Squibb	4	3
European Organisation for Research and Treatment of Cancer - EORTC	4	3
Hoffmann-La Roche	3	0
Janssen Research & Development, LLC	3	3

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.